Viatris agrees to buy Pacira for $1.65 billion
Viatris will pay $36.50 per share in cash for Pacira BioSciences, a roughly 45% premium to Pacira’s prior close, in a deal set to close by year-end.
Story updates
65 billion in a deal that expands the healthcare company's medicines portfolio. , company. The deal is slated to close by the end of the year. 47.
, company as a leader in non-opioid pain-management therapies. S. Food and Drug Administration is currently reviewing Viatris' application for the approval of meloxicam, with a target action date of Dec. 27.
Viatris said it plans to fund the Pacira acquisition primarily from excess cash, with the remainder from short-term borrowings, adding that it expects the deal will have minimal impact on its gross leverage ratio. com (END) Dow Jones Newswires October 08, 2026 08:25 ET (12:25 GMT) Copyright (c) 2026 Dow Jones & Company, Inc. The statements in this document shall not be considered as an objective or independent explanation of the matters.
Please note that this document (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and (b) is not subject to any prohibition on dealing ahead of the dissemination or publication of investment research.